Compounded Tirzepatide: FDA Status and Risks in 2027
Compounded tirzepatide is tirzepatide mixed by a compounding pharmacy or an outsourcing facility, not by the company that makes the drug. The FDA has not approved it. Only two tirzepatide drugs are approved: Mounjaro and Zepbound, both from Eli Lilly. The last grace period after the shortage, for outsourcing facilities, ended on 19 March 2025. Since then, pharmacies may copy the approved drug only in a few narrow cases.
As of November 2026, the FDA lists the tirzepatide shortage as resolved. That shortage is what let pharmacies make close copies of the approved drug. In 2026 the FDA also proposed keeping tirzepatide off the list of bulk ingredients that outsourcing facilities may compound from. That decision is still pending.
Peptides Vietnam checked every date and status on this page against FDA and Federal Register records on 6 November 2026. The page covers US federal rules only. It does not describe the law in Vietnam or any other country.
Quick answer
- FDA approved?
- No. Before a compounded drug is sold, the FDA does not review its safety, effectiveness or quality.
- Shortage status
- Resolved. The FDA confirmed it in a new decision on 19 December 2024, and its database still shows it as resolved in November 2026.
- Can pharmacies still make it?
- Only in narrow cases. The shortage exception is gone, so copies of the approved drug face tight limits.
- Pending decision
- The FDA proposed in April 2026 to keep tirzepatide off the 503B bulks list. Comments closed on 30 July 2026, and no final decision has been published.
- Same as Ozempic?
- No. Ozempic is semaglutide, a different medicine from Novo Nordisk that acts on one hormone receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1.
Sources: FDA human drug compounding page; FDA order on the tirzepatide shortage, 19 December 2024; FDA drug shortage database, tirzepatide injection; FDA statement on compounders and GLP-1 supply; Federal Register notice, 26 June 2026; Ozempic FDA label; Zepbound FDA label
What is compounded tirzepatide?
It is tirzepatide prepared by a compounder instead of a drug company. The FDA describes compounding as a licensed pharmacist or doctor combining, mixing or changing drug ingredients to make a medicine for one patient. At an outsourcing facility, the work happens under a licensed pharmacist's supervision.
Tirzepatide acts on two hormone receptors, GIP and GLP-1, according to its FDA label. Its approved brands are Mounjaro, used in type 2 diabetes, and Zepbound, used for weight reduction and for sleep apnea in certain adults. For the biology, see how tirzepatide works.
A compounded drug is not a generic. The FDA approves generic drugs, but it does not approve compounded ones. The FDA does say compounding can meet a real need, such as a patient who is allergic to a dye in an approved product.
Sources: FDA human drug compounding page; FDA compounding questions and answers; Zepbound FDA label; Mounjaro FDA label
What has the FDA done about compounded tirzepatide, and when?
We built this timeline from the primary records, not from news reports. We read the FDA's compounding statement, which has dated updates from 2 October 2024 to 1 April 2026. We also read its December 2024 order, both 2026 Federal Register notices in full, and the shortage database. On 6 November 2026 we searched the Federal Register for anything newer. The latest notice on the 503B bulks list is still the 26 June 2026 extension.
By our count, the dates show three gaps. Tirzepatide sat on the shortage list for 657 days before the FDA first found the shortage over. The last wind-down period ended 168 days after that finding. On 6 November 2026, the final 503B decision had been pending for 99 days since comments closed.
One date differs between FDA records. The FDA's 30 April 2026 press release gave 29 June as the comment deadline, while the Federal Register notice says 30 June. We use the Federal Register date, because that notice is the official document. Either way, the deadline later moved to 30 July 2026.
| Date | What happened | Record |
|---|---|---|
| 13 May 2022 | FDA approves Mounjaro, the first tirzepatide drug, for type 2 diabetes. | Drugs@FDA |
| 15 Dec 2022 | Tirzepatide injection goes on the FDA drug shortage list because of high demand. | FDA order, Dec 2024 |
| 8 Nov 2023 | FDA approves Zepbound for chronic weight management. | FDA press release |
| 2 Oct 2024 | FDA says the tirzepatide shortage is resolved. | FDA statement page |
| 7 and 11 Oct 2024 | Compounders sue. At the FDA's request, a court sends the decision back to the agency to review. | FDA order, Dec 2024 |
| 19 Dec 2024 | FDA issues a new decision that the shortage is resolved. Wind-down periods run to 18 Feb 2025 for 503A pharmacies and 19 Mar 2025 for 503B facilities. | FDA order; FDA statement page |
| 5 Mar 2025 | A federal court in Texas denies a preliminary injunction. The FDA says the 503A wind-down period is over. | FDA statement page, 10 Mar 2025 update |
| 19 Mar 2025 | The 503B wind-down period ends. | FDA statement page |
| Fall 2025 | During a crackdown on misleading drug ads that began in September, the FDA sends a first group of warning letters to telehealth firms. | FDA statements, Feb and Mar 2026 |
| 6 Feb 2026 | FDA says it intends to restrict GLP-1 ingredients meant for mass-marketed, unapproved compounded drugs. | FDA statement |
| 3 Mar 2026 | FDA announces a second group: 30 warning letters to telehealth companies over compounded GLP-1 claims. | FDA press release |
| 1 Apr 2026 | FDA reminds compounders that tirzepatide is on neither the 503B bulks list nor the shortage list. | FDA statement page |
| 30 Apr 2026 | FDA proposes not to add tirzepatide to the 503B bulks list. The Federal Register notice follows on 1 May. | FDA press release; 91 FR 23431 |
| 31 May 2026 | The FDA has more than 730 adverse event reports linked to compounded tirzepatide by this date. | FDA concerns page |
| 26 Jun 2026 | FDA extends the comment period on its proposal to 30 July 2026. | 91 FR 38719 |
| 6 Nov 2026 | No final 503B decision on tirzepatide found in the Federal Register. The shortage database still says resolved. | Our check of both |
Sources: Drugs@FDA, Mounjaro approval record; FDA order on the tirzepatide shortage, 19 December 2024; FDA press release, 8 November 2023; FDA statement on compounders and GLP-1 supply; FDA statement, 6 February 2026; FDA press release, 3 March 2026; FDA press release, 30 April 2026; Federal Register notice, 1 May 2026; FDA concerns with unapproved GLP-1 drugs; Federal Register notice, 26 June 2026; FDA drug shortage database, tirzepatide injection
Why did pharmacies start compounding tirzepatide?
Because the approved drug ran short. Tirzepatide injection went on the FDA drug shortage list on 15 December 2022 because of high demand. In US law, a shortage is a period when demand, or expected demand, for a drug in the United States is greater than its supply.
A shortage changes the compounding rules. While an approved drug is on the list, the FDA does not treat it as commercially available. So the usual limit on copying it does not apply. Outsourcing facilities may also make the drug from its active ingredient in bulk form, which the law calls a bulk drug substance.
By late 2024, the FDA described significant compounding of tirzepatide injection products. It also noted reports that some patients and pharmacists could not get the approved drugs.
Sources: FDA order on the tirzepatide shortage, 19 December 2024; FDA on compounding during drug shortages
When did the FDA say the tirzepatide shortage was over?
First on 2 October 2024, and again in a new decision on 19 December 2024. In October, the FDA said the maker's supply and production could meet present and projected US demand.
On 7 October 2024, the Outsourcing Facilities Association and a compounding company sued. At the FDA's request, a court sent the decision back to the agency on 11 October so it could look again.
The December decision revoked and replaced the first one. The FDA reviewed the maker's supply data and input from patients, health care providers and compounders. It concluded that supply was meeting or beating demand.
The FDA then gave compounders time to wind down. It said it would not act against shortage-related violations until 18 February 2025 for state-licensed pharmacies. For outsourcing facilities, the date was 19 March 2025. In February 2025 it added that each date would hold until a court ruled on the compounders' request, if that came later.
On 5 March 2025, a federal court in Texas denied that request for a preliminary injunction. The FDA said the pharmacy wind-down period had ended. The outsourcing facility period ran until 19 March 2025.
Even during the wind-down, the FDA kept the right to act on drugs that were poor quality or unsafe. As of November 2026, the FDA drug shortage database lists tirzepatide injection as resolved.
Sources: FDA statement on compounders and GLP-1 supply; FDA order on the tirzepatide shortage, 19 December 2024; FDA drug shortage database, tirzepatide injection
What are the rules for compounding tirzepatide now?
With the shortage over, the FDA generally treats the approved drugs as commercially available again. That brings back limits the shortage had lifted.
State-licensed pharmacies (section 503A)
A pharmacy must compound for an individual patient, based on a prescription. It may not regularly, or in inordinate amounts, make drugs that are essentially copies of a commercially available drug.
The FDA counts a compounded drug as essentially a copy when two things are true. It has the same active ingredient in the same, a similar or an easily substituted strength. And the approved drug can be given the same way. The exception is when a prescriber decides, and writes down, that a change makes a significant difference for an identified patient.
Adding an ingredient may not get around this. The FDA's own example is semaglutide mixed with vitamin B12, which it may still treat as a copy. For now, the FDA does not intend to act when a pharmacy fills four or fewer such prescriptions in a calendar month.
Outsourcing facilities (section 503B)
An outsourcing facility may use a bulk drug substance in two cases only. Either the substance is on the 503B bulks list, or the drug is on the shortage list when it is made and sent out. On 1 April 2026, the FDA said tirzepatide is on neither list. These facilities also may not make a drug that is essentially a copy of an approved drug unless that drug is in shortage.
Sources: FDA statement on compounders and GLP-1 supply; FDA on compounding during drug shortages
What is the difference between a 503A pharmacy and a 503B outsourcing facility?
They are the two legal routes for compounding under federal drug law. The 503B route was created by the Drug Quality and Security Act, signed on 27 November 2013.
The biggest practical gaps are oversight and reporting. The FDA inspects outsourcing facilities and requires them to report adverse events. State boards of pharmacy mainly oversee 503A pharmacies. Federal law does not make those pharmacies report adverse events to the FDA.
| Point | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Who it is | A licensed pharmacist in a state-licensed pharmacy or federal facility, or a doctor | A facility that compounds sterile drugs and has registered with the FDA as an outsourcing facility |
| Prescriptions | Compounds for an individual patient, based on a prescription | May or may not have patient prescriptions; can supply health care practitioners with office stock |
| Manufacturing rules | Not subject to current good manufacturing practice (CGMP) rules | Must follow CGMP rules |
| Main inspector | State boards of pharmacy, plus some FDA inspections | The FDA, on a risk-based schedule |
| Reports adverse events to the FDA | Not required by federal law | Required |
| Tirzepatide copies now | Not regularly or in large amounts, now that the shortage is over | Not from bulk tirzepatide, which is on neither the 503B bulks list nor the shortage list |
One more point from the FDA: it does not approve or license any pharmacy or outsourcing facility. It lists the claim that a compounded drug comes from an FDA-approved or FDA-licensed facility as false or misleading.
Sources: FDA compounding questions and answers; FDA information for outsourcing facilities; Federal Register notice, 1 May 2026; FDA concerns with unapproved GLP-1 drugs; FDA reminders to telehealth companies
What did the FDA propose about tirzepatide and the 503B bulks list in 2026?
On 30 April 2026, the FDA proposed not to put tirzepatide, semaglutide or liraglutide on the 503B bulks list. It found no clinical need for outsourcing facilities to compound them from bulk ingredients. The notice ran in the Federal Register on 1 May 2026.
Status on 6 November 2026: not final. We found no final notice on tirzepatide in the Federal Register. The FDA's 503B list page does not name tirzepatide as included or as not included, and the list itself shows an update date of 21 August 2023.
The FDA's first test asks two things. Does something about the approved drug make it medically unsuitable for certain patients? And is the compounded version meant to fix that? For tirzepatide, it tentatively found no basis to say yes, so it did not go further.
The nominations asked to compound tirzepatide as shots, tablets, capsules and forms held under the tongue or in the cheek. They also proposed mixes with pyridoxine or an anti-nausea medicine. The notice says no tirzepatide product is approved in pill, under-the-tongue or cheek form. See what exists in tirzepatide pills vs injection.
The FDA said the legal test is clinical need, not preference, so wanting a pill instead of a shot does not qualify. Discomfort from an injection does not make the approved drug unsuitable either. The FDA also does not count shortages, cost or convenience as clinical need.
Some nominations asked for strengths above the approved ones. The FDA said a better response at a higher dose would not make the approved product unsuitable. Eli Lilly and Company, which makes Mounjaro and Zepbound, filed a comment opposing the nomination.
Comments were due on 30 June 2026. After a request for more time, the FDA extended the deadline to 30 July 2026. It said the comments will inform its final decision on whether to include these substances.
Sources: FDA press release, 30 April 2026; Federal Register notice, 1 May 2026; Federal Register notice, 26 June 2026; FDA 503B bulks list page
What risks does the FDA name for compounded tirzepatide?
The core concern is that the FDA does not check a compounded drug before it is sold. Because compounded drugs skip FDA review for safety, effectiveness and quality, the FDA says they pose a higher risk than approved drugs. Its position is that they should be used only when an approved drug cannot meet a patient's medical needs. FDA pages on compounded drugs, and on compounded GLP-1 drugs in particular, name these problems:
- Quality. Poor compounding can cause contamination or too much or too little active ingredient, which can lead to serious injury or death. The FDA still finds unclean, or insanitary, conditions at compounding sites during inspections.
- Dosing. The FDA has reports of dosing errors with compounded semaglutide. It also has reports tied to compounded semaglutide or tirzepatide prescribed above the approved label doses. Symptoms included nausea, vomiting, diarrhea, belly pain and constipation.
- Multi-dose vials. Compounded GLP-1 drugs may come in vials that hold several doses. The FDA recommends throwing a vial away within 28 days of first use, even if medicine is left. After that, the risk of contamination rises.
- Warm shipping. The FDA has complaints of compounded GLP-1 drugs arriving warm. It recommends against using an injectable GLP-1 drug that shows up warm or poorly chilled.
- False labels. The FDA knows of compounded tirzepatide sold with false labels. Some name pharmacies that do not exist, and others name a real pharmacy that did not make the product.
- Missing directions. Labels on compounded drugs may leave out important information, such as adequate directions for safe use.
As of 31 May 2026, the FDA had more than 730 reports of adverse events linked to compounded tirzepatide. Federal law does not require state-licensed pharmacies to send these reports. So the FDA says such events are likely underreported. It adds that it cannot always tell whether the drug caused a reported problem.
Marketing is the other worry. On 3 March 2026, the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 drugs. The main problems were claims that implied sameness with approved drugs, and branding that hid who actually made the product.
The FDA lists red flags for telehealth sellers. They include deep discounts, no screening or prescription by a licensed doctor, and claims that a compounded drug matches an approved one. The FDA asks patients and health professionals to report problems with any medicine to its MedWatch program.
Sources: FDA concerns with unapproved GLP-1 drugs; FDA on compounding during drug shortages; FDA compounding questions and answers; FDA on the risks of compounded drugs; FDA press release, 3 March 2026
How is Mounjaro or Zepbound different from compounded tirzepatide?
Both hold tirzepatide, but the checks around them differ. As of November 2026, FDA records list two approved tirzepatide drugs, Mounjaro and Zepbound, and both are injections.
The sharpest difference is the check before sale. For an approved drug, the FDA reviews safety, effectiveness and quality. It also assesses the plant, including a site inspection. For a compounded drug, there is no FDA review before sale, and the FDA does not assess the maker of a bulk ingredient before it is used.
| Point | Mounjaro or Zepbound | Compounded tirzepatide |
|---|---|---|
| FDA review before sale | Reviewed for safety, effectiveness and quality | Not reviewed |
| Factory checks | Plant assessed before approval, including a site inspection, then routine inspections | The FDA does not assess the maker of a bulk ingredient before it is used in compounding |
| Approved uses | Zepbound: long-term weight reduction and obstructive sleep apnea in certain adults. Mounjaro: type 2 diabetes, for adults and for children aged 10 or older, and a lower chance of major heart problems for high-risk adults with diabetes | None |
| Label | FDA-approved prescribing information, a boxed warning about thyroid C-cell tumors and a Medication Guide | May leave out important information, such as adequate directions for use |
| Ingredients | Tirzepatide plus a short list of inactive ingredients, with no vitamins | Some nominations proposed mixing in other ingredients; the FDA has not reviewed such mixes |
Mounjaro and Zepbound contain the same medicine under two brand names with different approved uses. For the label differences, see is Zepbound the same as Mounjaro.
Sources: Zepbound FDA label; Mounjaro FDA label; openFDA Drugs@FDA data, tirzepatide applications; Federal Register notice, 1 May 2026; FDA on the risks of compounded drugs; FDA press release, 8 November 2023
What is still pending going into 2027?
This list holds only steps the FDA has started and not finished. It makes no predictions.
- The final 503B decision. The FDA said comments on its April 2026 proposal will inform a final decision on tirzepatide, semaglutide and liraglutide. Under its process, that final decision is published in the Federal Register. Neither notice we read gives a date.
- Limits on GLP-1 ingredients. In February 2026, the FDA said it intends to restrict GLP-1 active ingredients meant for unapproved compounded drugs. It already runs an import alert, 66-80, to keep GLP-1 ingredients with possible quality concerns out of the US supply chain.
- Shortage status. The shortage list drives the copy rules. If an approved drug is back on the list, some limits on copies do not apply while it stays there. As of November 2026, tirzepatide is listed as resolved.
Sources: Federal Register notice, 1 May 2026; Federal Register notice, 26 June 2026; FDA statement, 6 February 2026; FDA concerns with unapproved GLP-1 drugs; FDA on compounding during drug shortages; FDA drug shortage database, tirzepatide injection
Compounded tirzepatide questions
What is the difference between tirzepatide and compounded tirzepatide?+
Tirzepatide is the medicine in Mounjaro and Zepbound, which the FDA has approved. Compounded tirzepatide is a version mixed by a pharmacy or an outsourcing facility. The FDA gives compounded drugs no safety, effectiveness or quality review before sale, and it says they are not generics. Since the shortage ended, copies of the approved drug face tight limits.
Is Ozempic the same as compounded tirzepatide?+
No. Ozempic is a brand of semaglutide, a different medicine made by Novo Nordisk. Its FDA label is for adults with type 2 diabetes. Semaglutide acts on one hormone receptor, GLP-1. Tirzepatide acts on two, GIP and GLP-1. Its approved brands are Mounjaro and Zepbound, from Eli Lilly and Company. Compounded tirzepatide is a version made by a compounder, and the FDA has not approved it. The FDA's April 2026 proposal to leave semaglutide and tirzepatide off the 503B bulks list also named liraglutide.
Does compounded tirzepatide work as well as Zepbound?+
No official source can say, because the FDA has never reviewed a compounded version for effectiveness. Zepbound was tested in two placebo-controlled trials before its approval. The FDA has also told telehealth companies not to call a compounded drug clinically proven to match the results of an approved drug.
What are the typical dosages for tirzepatide?+
The FDA labels for Zepbound and Mounjaro, both updated in August 2026, list these doses for the approved brands, each injected under the skin once a week:
Zepbound: 2.5 mg for the first 4 weeks, then 5 mg. Each later increase is 2.5 mg, made no sooner than 4 weeks after the last change. Maintenance is 5 mg, 10 mg or 15 mg for weight reduction, and 10 mg or 15 mg for sleep apnea. The maximum is 15 mg.
Mounjaro: 2.5 mg to start. When blood sugar needs more control, the label allows 2.5 mg increases, each one at least 4 weeks apart. The maximum is 15 mg for adults and 10 mg for children aged 10 and older.
Disclaimer: this is FDA label information for education, not medical advice and not a dose for any reader. Follow your prescriber.
These figures belong to the approved brands only. The FDA has not reviewed any compounded version, and it has reports of compounded tirzepatide prescribed above the approved label doses.
Is tirzepatide compounded with niacinamide safe?+
There is no FDA finding either way, because the FDA does not review compounded mixes. Neither the Mounjaro nor the Zepbound label lists niacinamide or any vitamin among its ingredients. The FDA has also said an added ingredient may not stop a drug from counting as a copy. Its example was vitamin B12 mixed with semaglutide.
Is tirzepatide red?+
Not in its approved form. The Zepbound and Mounjaro labels describe a clear solution that is colorless to slightly yellow. The FDA does not review compounded versions before sale, so no FDA label says how a compounded product should look.
What are the common side effects of GLP-1 drugs like tirzepatide?+
For tirzepatide, the Zepbound label lists the side effects that 5% or more of patients reported. Nausea, vomiting, diarrhea and constipation lead that list. It also has belly pain, indigestion, burping, acid reflux, tiredness, hair loss, allergic reactions and injection site reactions. The FDA says many adverse events reported for compounded versions look like those of the approved drugs.
Is compounded tirzepatide still legal in 2026?+
Only in narrow cases, under FDA rules as of November 2026. The shortage exception ended in 2025. A state-licensed pharmacy needs a prescription for an individual patient. It may not make copies of the approved drug regularly or in large amounts. Outsourcing facilities may not compound from bulk tirzepatide, because it is on neither the shortage list nor the 503B bulks list. The FDA has not yet published its final 503B decision on tirzepatide, so that question carries into 2027 with no set date.
Sources: FDA compounding questions and answers; FDA press release, 8 November 2023; FDA reminders to telehealth companies; Zepbound FDA label; Mounjaro FDA label; FDA statement on compounders and GLP-1 supply; FDA concerns with unapproved GLP-1 drugs; Ozempic FDA label; FDA press release, 30 April 2026; Federal Register notice, 1 May 2026; Federal Register notice, 26 June 2026
Related tirzepatide guides
This explainer is for learning, not medical or legal advice. It reports what US regulators and the approved labels say about compounded tirzepatide. Decisions about a specific medicine belong with a licensed clinician.